NCT06745622View on ClinicalTrials.gov

Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

HSK39297 tablets

HSK39297 tablets until the end of treatment

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY